These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 38677200)

  • 1. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
    Jiang M; Li Q; Xu B
    Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Picking the optimal target for antibody-drug conjugates.
    Mathur R; Weiner GJ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.
    Ascione L; Guidi L; Prakash A; Trapani D; LoRusso P; Lou E; Curigliano G
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431766. PubMed ID: 38828973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads.
    Tonon G; Rizzolio F; Visentin F; Scattolin T
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Loganzo F; Sung M; Gerber HP
    Mol Cancer Ther; 2016 Dec; 15(12):2825-2834. PubMed ID: 27780876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G
    Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
    Zhang B; Wang M; Sun L; Liu J; Yin L; Xia M; Zhang L; Liu X; Cheng Y
    J Med Chem; 2024 Jul; 67(14):11469-11487. PubMed ID: 38980167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in cancer-targeted antibody-drug conjugates.
    Bidard FC; Trédan O
    Target Oncol; 2014 Mar; 9(1):1-8. PubMed ID: 24221961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
    Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
    Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Basics and Innovations in Antibody-Drug Conjugates].
    Manabe S
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):681-685. PubMed ID: 39191680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity.
    Dong W; Wang W; Cao C
    ChemMedChem; 2024 Sep; 19(17):e202400109. PubMed ID: 38758596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
    Barok M; Puhka M; Yazdi N; Joensuu H
    J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update.
    Dias E Silva D; Andriatte GM; Pestana RC
    Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.